Chinese Familial Hypercholesterolemia Management Based on Guidelines
WEN Wenhui1,2,KUANG Zemin3,WANG Lyuya1,2*
1.Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China
2.Atherosclerosis Research Laboratory,Beijing Institute of Heart Lung and Blood Vessel Diseases,Beijing 100000,China
3.Department of Hypertension,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China
*Corresponding author:WANG Lyuya,Doctoral supervisor,Professor;E-mail:wangluya@126.com
[1]中华医学会心血管病学分会动脉粥样硬化及冠心病学组,中华心血管病杂志编辑委员会.家族性高胆固醇血症筛查与诊治中国专家共识[J].中华心血管病杂志,2018,46(2):99-103.DOI:10.3760/cma.j.issn.0253-3758.2018.02.006.
Atherosclerosis and Coronary Heart Disease Group,Chinese Society of Cardiology,Editorial Board of Chinese Journal of Cardiology.Expert consensus on screening and diagnosis of familial hypercholesterolemia in China[J].Chinese Journal of Cardiology,2018,46(2):99-103.DOI:10.3760/cma.j.issn.0253-3758.2018.02.006.
[2]DO R,STITZIEL N O,WON H H,et al.Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction[J].Nature,2015,518(7537):102-106.DOI:10.1038/nature13917.
[3]MYANT N B.Familial defective apolipoprotein B-100:a review,including some comparisons with familial hypercholesterolaemia[J].Atherosclerosis,1993,104(1/2):1-18.
[4]COHEN J C,BOERWINKLE E,MOSLEY T H,et al.Sequence variations in PCSK9,low LDL,and protection against coronary heart disease[J].N Engl J Med,2006,354(12):1264-1272.DOI:10.1056/NEJMoa054013.
[5]FERENCE B A,GRAHAM I,TOKGOZOGLU L,et al.Impact of lipids on cardiovascular health:JACC health promotion series[J].J Am Coll Cardiol,2018,72(10):1141-1156.DOI:10.1016/j.jacc.2018.06.046.
[6]MACCHIAIOLO M,GAGLIARDI M G,TOSCANO A,et al.Homozygous familial hypercholesterolaemia[J].Lancet,2012,379(9823):1330.DOI:10.1016/S0140-6736(11)61476-1.
[7]SLACK J.Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states[J].Lancet,1969,2(7635):1380-1382.
[8]STONE N J,LEVY R I,FREDRICKSON D S,et al.Coronary artery disease in 116 kindred with familial typeⅡ hyperlipoproteinemia[J].Circulation,1974,49(3):476-488.
[9]MABUCHI H,NOHARA A,NOGUCHI T,et al.Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan[J].Atherosclerosis,2011,214(2):404-407.DOI:10.1016/j.atherosclerosis.2010.11.005.
[10]NORDESTGAARD B G,CHAPMAN M J,HUMPHRIES S E,et al.Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population:guidance for clinicians to prevent coronary heart disease:consensus statement of the European Atherosclerosis Society[J].Eur Heart J,2013,34(45):3478-3490a.DOI:10.1093/eurheartj/eht273.
[11]ZHOU M,ZHAO D.Familial hypercholesterolemia in Asian populations[J].J Atheroscler Thromb,2016,23(5):539-549.DOI:10.5551/jat.34405.
[12]CUCHEL M,BRUCKERT E,GINSBERG H N,et al.Homozygous familial hypercholesterolaemia:new insights and guidance for clinicians to improve detection and clinical management.A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society[J].Eur Heart J,2014,35(32):2146-2157.DOI:10.1093/eurheartj/ehu274.
[13]CIVEIRA F.Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia[J].Atherosclerosis,2004,173(1):55-68.DOI:10.1016/j.atherosclerosis.2003.11.010.
[14]Mortality in treated heterozygous familial hypercholesterolaemia:implications for clinical management.Scientific Steering Committee on behalf of the Simon Broome Register Group[J].Atherosclerosis,1999,142(1):105-112.
[15]GIDDING S S,CHAMPAGNE M A,DE FERRANTI S D,et al.The agenda for familial hypercholesterolemia:a scientific statement from the American Heart Association[J].Circulation,2015,132(22):2167-2192.DOI:10.1161/CIR.0000000000000297.
[16]HUMPHRIES S E,NORBURY G,LEIGH S,et al.What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia[J].Curr Opin Lipidol,2008,19(4):362-368.DOI:10.1097/MOL.0b013e32830636e5.
[17]WATTS G F,GIDDING S,WIERZBICKI A S,et al.Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation[J].Int J Cardiol,2014,171(3):309-325.DOI:10.1016/j.ijcard.2013.11.025.
[18]STURM A C,KNOWLES J W,GIDDING S S,et al.Clinical genetic testing for familial hypercholesterolemia:JACC scientific expert panel[J].J Am Coll Cardiol,2018,72(6):662-680.DOI:10.1016/j.jacc.2018.05.044.
[19]SHI Z,YUAN B,ZHAO D,et al.Familial hypercholesterolemia in China:prevalence and evidence of underdetection and undertreatment in a community population[J].Int J Cardiol,2014,174(3):834-836.DOI:10.1016/j.ijcard.2014.04.165.
[20]WATTS G F,GIDDING S,WIERZBICKI A S,et al.Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation:executive summary[J].J Atheroscler Thromb,2014,21(4):368-374.
[21]Correction to Lancet Diabetes Endocrinol 2016;published online May 27.http://dx.DOI.org/10.1016/S2213-8587(16)30041-9
[J].Lancet Diabetes Endocrinol,2016,pii:S2213-8587(16)30150-4.DOI:10.1016/S2213-8587(16)30150-4.
[22]CATAPANO A L,GRAHAM I,DE BACKER G,et al.2016 ESC/EAS guidelines for the management of dyslipidaemias:the task force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and European Atherosclerosis Society(EAS)developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation(EACPR)[J].Atherosclerosis,2016,253:281-344.DOI:10.1016/j.atherosclerosis.2016.08.018.
[23]中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937-950.DOI:10.3969/j.issn.1000-3614.2016.10.001.
Joint Committee on Revision of Guidelines for Prevention and Treatment of Adult Hyperlipidemia in China.2016 Chinese guideline for the management of dyslipidemia in adults[J].Chinese Circulation Journal,2016,31(10):937-950.DOI:10.3969/j.issn.1000-3614.2016.10.001.
[24]RAAL F J,HONARPOUR N,BLOM D J,et al.Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia(TESLA Part B):a randomised,double-blind,placebo-controlled trial[J].Lancet,2015,385(9965):341-350.DOI:10.1016/S0140-6736(14)61374-X.
[25]RAY K K,LANDMESSER U,LEITER L A,et al.Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J].N Engl J Med,2017,376(15):1430-1440.DOI:10.1056/NEJMoa1615758.
[26]DEWEY F E,GUSAROVA V,DUNBAR R L,et al.Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease[J].N Engl J Med,2017,377(3):211-221.DOI:10.1056/NEJMoa1612790.
[27]GAUDET D,GIPE D A,PORDY R,et al.ANGPTL3 inhibition in homozygous familial hypercholesterolemia[J].N Engl J Med,2017,377(3):296-297.DOI:10.1056/NEJMc1705994.
[28]Endotext[M].South Dartmouth:MDText.com,Inc,2000.
[29]“中国家族性高胆固醇血症门诊筛查项目”签约和启动仪式在沪顺利召开[J].中国介入心脏病学杂志,2016,24(6):342.
The signing and launching ceremony of“China Family Hypercholesterolemia Outpatient Screening Project”was successfully held in Shanghai[J].Chinese Journal of Interventional Cardiology,2016,24(6):342.
[30]中国国家罕见病注册登记系统[J].科技导报,2017,35(16):99.
National rare diseases registry system of China[J].Science & Technology Review,2017,35(16):99.
[31]中国家族性高胆固醇血症门诊筛查项目正式启动[EB/OL].(2016-06-03)[2018-11-15].http://meeting.dxy.cn/article/495139.
[32]王伟,杨娅,王蒨,等.多学科合作更好管理纯合型家族性高胆固醇血症——安贞医院经验[J].中国介入心脏病学杂志,2017,25(11):658-660.DOI:10.3969/j.issn.1004-8812.2017.11.012.
WANG W,YANG Y,WANG Q,et al.Multidisciplinary cooperation to better manage homozygous familial hypercholesterolemia:Anzhen Hospital experience[J].Chinese Journal of Interventional Cardiology,2017,25(11):658-660.DOI:10.3969/j.issn.1004-8812.2017.11.012.
[33]LANGSTED A,KAMSTRUP P R,BENN M,et al.High lipoprotein(a)as a possible cause of clinical familial hypercholesterolaemia:a prospective cohort study[J].Lancet Diabetes Endocrinol,2016,4(7):577-587.DOI:10.1016/S2213-8587(16)30042-0.
[34]LI S,ZHANG Y,ZHU C G,et al.Identification of familial hypercholesterolemia in patients with myocardial infarction:a Chinese cohort study[J].J Clin Lipidol,2016,10(6):1344-1352.DOI:10.1016/j.jacl.2016.08.013.
[35]PAPADEMETRIOU V,STAVROPOULOS K,PAPADOPOULOS C,et al.Role of PCSK9 inhibitors in high risk patients with dyslipidemia:focus on familial hypercholesterolemia[J].Curr Pharm Des,2018.DOI:10.2174/1381612824666181010124657.
[36]我国首个PCSK9类降脂药瑞百安正式获批[EB/OL].(2018-08-10)[2018-11-15].http://www.cpi.gov.cn/publish/default/hyzx/content/2018080914190611440.htm.